Warner, Louise
March 1963
Angiology;Mar1963, Vol. 14 Issue 3, p116
Academic Journal
The number of blood vessels per cubic millimeter of tumor tissue seems to be greatest first, when the tumor begins to grow (cf. frog I, 56th day after inoculation), and then subsides until the tumor starts to regress, when the blood vessels increase again (cf. frogs I and IV on the 84th day after inoculation). The validity of this statement can be tested in future series of animals.


Related Articles

  • A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. Wei Sun; Fan, Yue Z.; Zhang, Wen Z.; Ge, Chun Y. // Journal of Experimental & Clinical Cancer Research (17569966);2011, Vol. 30 Issue 1, p46 

    Background: Vasculogenic mimicry (VM), as a new blood supply for tumor growth and hematogenous metastases, has been recently described in highly aggressive human melanoma cells, etc. We previously reported VM in human gallbladder carcinomas and its clinical significance. In this study, we...

  • Unusual Manifestations of Renal Cell Carcinoma. Sung Bin Park; Kyoung-Sik Cho; Jong Hwa Lee; Yoong Ki Jeong; Seong Hoon Choi; Byeong Seong Kang; Jeong Kon Kim // Acta Radiologica;Sep2008, Vol. 49 Issue 7, p839 

    The imaging characteristics of renal cell carcinoma (RCC) vary widely, with masses ranging from cystic to solid, from homogeneous to heterogeneous and necrotic, from small to large, and from localized to extensive. Although the usual imaging features of RCC are well known to radiologists,...

  • DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature. Chi Sabins, Nina; Taylor, Jennifer L; Fabian, Kellsye PL; Appleman, Leonard J; Maranchie, Jodi K; Stolz, Donna Beer; Storkus, Walter J // Molecular Therapy;Oct2013, Vol. 21 Issue 10, p1958 

    Tumor blood vessels are frequently inefficient in their design and function, leading to high interstitial fluid pressure, hypoxia, and acidosis in the tumor microenvironment (TME), rendering tumors refractory to the delivery of chemotherapeutic agents and immune effector cells. Here we...

  • Pazopanib.  // Australian Prescriber;Dec2010, Vol. 33 Issue 6, p197 

    The article provides information on Pazopanib, a drug intended for metastatic renal cell carcinoma, from GlaxoSmithKline. Pazopanib is claimed to not only inhibits the formation of new blood vessels and prevents the growth of tumour, but also inhibits tyrosine kinase. Meanwhile, its approval is...

  • the Straight DOPE. ADAMS, CECIL // Athens News;2/10/2014, p23 

    The article provides an answer to a question of would the transplanted tumor grows after a cancerous tumor transplanted from one person to another.

  • Successful renal transplantation after two separate urinary tract malignancies. Joshi, Rohit; Mammen, Kim; Pawar, Basant // Indian Journal of Urology;Apr-Jun2008, Vol. 24 Issue 2, p256 

    A patient who was treated for renal cell carcinoma and transitional cell carcinoma, later presented with end stage renal disease. He was managed with hemodialysis and later underwent successful renal transplantation. There was no evidence of tumor recurrence nearly nine years post-renal...

  • Incidental renal cell carcinoma identified during laparoscopic live-related donor nephrectomy. Bycroft, John A.; Benaragama, Kapila S. D.; Green, Anna; Lindsey, Benjamin; Nicol, David L. // JRSM Shorts;Sep2010, Vol. 1 Issue 4, p1 

    The article presents a case study of a 41-year-old man with conventional vascular anatomy and hypodense lesion who will undergo a left laparoscopic live donor nephrectomy. The patient underwent laparoscopic donor nephrectomy in which a fully excised papillary renal cell carcinoma was excised....

  • Partial nephrectomy for renal cell carcinoma in an allograft kidney with limited functional reserve. Li, Jordan Y. Z.; Yong, Tuck Y.; Rao, Mohan; Coates, P. Toby H. // NDT Plus;Aug2009, Vol. 2 Issue 4, p312 

    The increased risk of malignancies is a well-recognized complication of organ transplantation. When renal cell carcinoma (RCC) occurs in kidney transplant recipients, less than 10% of it affects the allograft. Recent experience suggests that partial allograft nephrectomy for tumours less than 4...

  • Renal Cell Carcinoma in a kidney allograft 11 years after renal transplant. Taj, Asma; Muzaffar, Mehvish; Sheikh, Rehmat Ullah; Qadir, Rehana; Ratnam, Shobha // Internet Journal of Oncology;2009, Vol. 6 Issue 2, p18 

    Malignancies are common after renal transplant because of immunosuppression. Renal cell carcinoma is common but occurs in the native kidney. Carcinoma in the transplant kidney is less common but has been reported with an average interval of 3 to 4 years after transplant. We report a case of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics